Previous 10 | Next 10 |
2024-01-17 12:48:13 ET More on INVO BioScience Invo to acquire Naya Biosciences in all-stock deal Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience For further...
PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
2023-12-19 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, M...
2023-11-14 13:01:05 ET Nanobiotix S.A. (NBTX) Q3 2023 Earnings Conference Call November 14, 2023, 08:00 AM ET Company Participants Craig West - Senior Vice President of Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chie...
$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline St...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
PARIS and CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities f...
PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand t...
2023-11-02 11:54:36 ET More on Nanobiotix Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript Nanobiotix: At A Crucial Juncture For Data Nanobiotix: French Radiation Enhancer Developer With A Major JNJ Deal Biggest stock movers today: PHG, Pioneer Natural...
News, Short Squeeze, Breakout and More Instantly...
Nanobiotix S.A. Company Name:
NBTX Stock Symbol:
NASDAQ Market:
PARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering ph...
PARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for pati...
PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatme...